Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Lyra Therapeutics, Inc. (LYRA)
Company Research
Source: Yahoo! Finance
– In parallel, the company continues to analyze data from ENLIGHTEN 1; further analysis of the ENLIGHTEN 1 data has revealed that LYR-210 demonstrated improvement over control in symptomatic endpoints in the CRS patient cohort with nasal polyps – WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the second quarter ended June 30, 2024 and provided a corporate update. “While we clearly recognize the disappointment of not meeting the primary endpoint in the previously-announced ENLIGHTEN 1 Phase 3 trial, our potential pathway to approval for LYR-210 in CRS without nasal polyps can only be determined once we unblind and analyze the full data set from the ENLIGHTEN pivotal program,” said Maria Palasis, Ph.D., President and CEO of
Show less
Read more
Impact Snapshot
Event Time:
LYRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYRA alerts
High impacting Lyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LYRA
News
- Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual MeetingsGlobeNewswire
- Lyra Therapeutics, Inc. (NASDAQ: LYRA) was upgraded by analysts at William Blair to a "hold" rating.MarketBeat
- Lyra Therapeutics Insiders Still US$66k Away From Original Investment Value [Yahoo! Finance]Yahoo! Finance
- Lyra Therapeutics, Inc. (NASDAQ: LYRA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.MarketBeat
- Lyra Therapeutics, Inc. (NASDAQ: LYRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
LYRA
Sec Filings
- 8/15/24 - Form SC
- 8/14/24 - Form 10-Q
- 8/14/24 - Form 8-K
- LYRA's page on the SEC website